PRL and neoplasm: According to the most recent Pituitary Society international Consensus Statement, DA resistance is defined as a failure to achieve a normal PRL level or a \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\:\ge\:30$$\end{document}% reduction in tumor size despite treatment with maximally tolerated doses of DA therapy for 3–6 months [5].